Первичный гиперальдостеронизм как возможная причина резистентного течения артериальной гипертонии
Первичный гиперальдостеронизм как возможная причина резистентного течения артериальной гипертонии
Чихладзе Н.М. Первичный гиперальдостеронизм как возможная причина резистентного течения артериальной гипертонии. Системные гипертензии. 2020; 17 (4): 20–23. DOI: 10.26442/2075082X.2020.4.200338
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В обзоре рассматривается распространенность резистентного течения артериальной гипертонии (АГ) при низкорениновых формах гиперальдостеронизма. Проанализированы возможные причины существующих различий в данных по распространенности гетерогенной группы первичного гиперальдостеронизма (ПГА) при резистентном течении АГ. Рассмотрены категории пациентов высокого риска развития ПГА в зависимости от тяжести течения АГ. По результатам проведенных исследований, включая собственные данные, показано, что в большинстве случаев опухолевые и гиперпластические формы ПГА ассоциированы с тяжелым и резистентным течением АГ, обосновывается важность проведения диагностического скрининга у этой категории пациентов.
Ключевые слова: первичный гиперальдостеронизм, резистентная артериальная гипертония, распространенность.
Key words: primary hyperaldosteronism, resistant arterial hypertension, prevalence.
Ключевые слова: первичный гиперальдостеронизм, резистентная артериальная гипертония, распространенность.
________________________________________________
Key words: primary hyperaldosteronism, resistant arterial hypertension, prevalence.
Список литературы
1. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension. Eur Heart J 2018; 39: 3021–104.
2. Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117 (25): e510–26.
3. Daugherty SL, Powers JD, Magid DJ et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125 (13): 1635–42.
4. Petramala L, Olmati F, Galassi M et al. The prevalence of resistant arterial hypertension and secondary causes in a cohort of hypertensive patients: a single center experience. Italian Journal of Medicine 2017; 11 (4): 380–7.
5. Mosso L, Carvajal C, González A et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42 (2): 161–5.
6. Strauch B, Zelinka T, Hampf M. et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003; 17 (5): 349–52.
7. Douma S, Petidis K, Doumas M et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational. Lancet 2008; 371 (9628): 1921–6.
8. Käyser SC, Dekkers T, Groenewoud HJ et al. Study Heterogeneity and Estimation of Prevalence of Primary Aldosteronism: A Systematic Review and Meta-Regression Analysis. J Clin Endocrinol Metab 2016; 101 (7): 2826–35.
9. Monticone S, Burrello J, Tizzani D et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol 2017; 69 (14): 1811–20.
10. Funder JW, Carey RM, Mantero F et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101 (5): 1889–916.
11. Самедова Х.Ф., Чихладзе Н.М., Блинова Е.В. и др. Оценка функционального состояния миокарда у больных артериальной гипертонией на фоне гиперальдостеронизма с использованием ортогональной электрокардиографии. Кардиоваскулярная терапия и профилактика. 2006; 5 (2): 15–9.
[Samedova Kh.F., Chikhladze N.M., Blinova E.V. et al. Otsenka funktsional'nogo sostoianiia miokarda u bol'nykh arterial'noi gipertoniei na fone giperal'dosteronizma s ispol'zovaniem ortogonal'noi elektrokardiografii. Kardiovaskuliarnaia terapiia i profilaktika. 2006; 5 (2): 15–9 (in Russian).]
12. Stowasser M, Bachmann AW, Huggard PR et al. Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance. J Clin Endocrinol Metab 2000; 85 (6): 2160–6.
13. Чихладзе Н.М., Фаворова О.О., Чазова И.Е. Семейная форма гиперальдостеронизма I типа: клиническое наблюдение и обзор литературы. Терапевтический архив. 2018; 90 (9): 115–22.
[Chikhladze N.M., Favorova O.O., Chazova I.E. Familial type I hyperaldosteronism: clinical observation and literature review. Therapeutic Archive. 2018; 90 (9): 115–22 (in Russian).]
14. Schmiemann G, Gebhardt K, Hummers-Pradier E et al. Prevalence of hyperaldosteronism in primary care patients with resistant hypertension. J Am Board Fam Med 2012; 25: 98–103.
15. Sang X, Jiang Y, Wang W et al. Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China. J Hypertens 2013; 31 (7): 1465–72.
16. Catena C, Colussi G, Nadalini E et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 80–5.
17. Milliez P, Girerd X, Plouin PF et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45 (8): 1243–8.
18. Jaffe G, Gray Z, Krishna G et al. Screening Rates for Primary Aldosteronism in Resistant Hypertension. A Cohort Study. Hypertension 2020; 75 (3): 650–9.
2. Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117 (25): e510–26.
3. Daugherty SL, Powers JD, Magid DJ et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125 (13): 1635–42.
4. Petramala L, Olmati F, Galassi M et al. The prevalence of resistant arterial hypertension and secondary causes in a cohort of hypertensive patients: a single center experience. Italian Journal of Medicine 2017; 11 (4): 380–7.
5. Mosso L, Carvajal C, González A et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42 (2): 161–5.
6. Strauch B, Zelinka T, Hampf M. et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003; 17 (5): 349–52.
7. Douma S, Petidis K, Doumas M et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational. Lancet 2008; 371 (9628): 1921–6.
8. Käyser SC, Dekkers T, Groenewoud HJ et al. Study Heterogeneity and Estimation of Prevalence of Primary Aldosteronism: A Systematic Review and Meta-Regression Analysis. J Clin Endocrinol Metab 2016; 101 (7): 2826–35.
9. Monticone S, Burrello J, Tizzani D et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol 2017; 69 (14): 1811–20.
10. Funder JW, Carey RM, Mantero F et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101 (5): 1889–916.
11. Samedova Kh.F., Chikhladze N.M., Blinova E.V. et al. Otsenka funktsional'nogo sostoianiia miokarda u bol'nykh arterial'noi gipertoniei na fone giperal'dosteronizma s ispol'zovaniem ortogonal'noi elektrokardiografii. Kardiovaskuliarnaia terapiia i profilaktika. 2006; 5 (2): 15–9 (in Russian).
12. Stowasser M, Bachmann AW, Huggard PR et al. Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance. J Clin Endocrinol Metab 2000; 85 (6): 2160–6.
13. Chikhladze N.M., Favorova O.O., Chazova I.E. Familial type I hyperaldosteronism: clinical observation and literature review. Therapeutic Archive. 2018; 90 (9): 115–22 (in Russian).
14. Schmiemann G, Gebhardt K, Hummers-Pradier E et al. Prevalence of hyperaldosteronism in primary care patients with resistant hypertension. J Am Board Fam Med 2012; 25: 98–103.
15. Sang X, Jiang Y, Wang W et al. Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China. J Hypertens 2013; 31 (7): 1465–72.
16. Catena C, Colussi G, Nadalini E et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 80–5.
17. Milliez P, Girerd X, Plouin PF et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45 (8): 1243–8.
18. Jaffe G, Gray Z, Krishna G et al. Screening Rates for Primary Aldosteronism in Resistant Hypertension. A Cohort Study. Hypertension 2020; 75 (3): 650–9.
2. Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117 (25): e510–26.
3. Daugherty SL, Powers JD, Magid DJ et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125 (13): 1635–42.
4. Petramala L, Olmati F, Galassi M et al. The prevalence of resistant arterial hypertension and secondary causes in a cohort of hypertensive patients: a single center experience. Italian Journal of Medicine 2017; 11 (4): 380–7.
5. Mosso L, Carvajal C, González A et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42 (2): 161–5.
6. Strauch B, Zelinka T, Hampf M. et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003; 17 (5): 349–52.
7. Douma S, Petidis K, Doumas M et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational. Lancet 2008; 371 (9628): 1921–6.
8. Käyser SC, Dekkers T, Groenewoud HJ et al. Study Heterogeneity and Estimation of Prevalence of Primary Aldosteronism: A Systematic Review and Meta-Regression Analysis. J Clin Endocrinol Metab 2016; 101 (7): 2826–35.
9. Monticone S, Burrello J, Tizzani D et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol 2017; 69 (14): 1811–20.
10. Funder JW, Carey RM, Mantero F et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101 (5): 1889–916.
11. Самедова Х.Ф., Чихладзе Н.М., Блинова Е.В. и др. Оценка функционального состояния миокарда у больных артериальной гипертонией на фоне гиперальдостеронизма с использованием ортогональной электрокардиографии. Кардиоваскулярная терапия и профилактика. 2006; 5 (2): 15–9.
[Samedova Kh.F., Chikhladze N.M., Blinova E.V. et al. Otsenka funktsional'nogo sostoianiia miokarda u bol'nykh arterial'noi gipertoniei na fone giperal'dosteronizma s ispol'zovaniem ortogonal'noi elektrokardiografii. Kardiovaskuliarnaia terapiia i profilaktika. 2006; 5 (2): 15–9 (in Russian).]
12. Stowasser M, Bachmann AW, Huggard PR et al. Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance. J Clin Endocrinol Metab 2000; 85 (6): 2160–6.
13. Чихладзе Н.М., Фаворова О.О., Чазова И.Е. Семейная форма гиперальдостеронизма I типа: клиническое наблюдение и обзор литературы. Терапевтический архив. 2018; 90 (9): 115–22.
[Chikhladze N.M., Favorova O.O., Chazova I.E. Familial type I hyperaldosteronism: clinical observation and literature review. Therapeutic Archive. 2018; 90 (9): 115–22 (in Russian).]
14. Schmiemann G, Gebhardt K, Hummers-Pradier E et al. Prevalence of hyperaldosteronism in primary care patients with resistant hypertension. J Am Board Fam Med 2012; 25: 98–103.
15. Sang X, Jiang Y, Wang W et al. Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China. J Hypertens 2013; 31 (7): 1465–72.
16. Catena C, Colussi G, Nadalini E et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 80–5.
17. Milliez P, Girerd X, Plouin PF et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45 (8): 1243–8.
18. Jaffe G, Gray Z, Krishna G et al. Screening Rates for Primary Aldosteronism in Resistant Hypertension. A Cohort Study. Hypertension 2020; 75 (3): 650–9.
________________________________________________
2. Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117 (25): e510–26.
3. Daugherty SL, Powers JD, Magid DJ et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125 (13): 1635–42.
4. Petramala L, Olmati F, Galassi M et al. The prevalence of resistant arterial hypertension and secondary causes in a cohort of hypertensive patients: a single center experience. Italian Journal of Medicine 2017; 11 (4): 380–7.
5. Mosso L, Carvajal C, González A et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42 (2): 161–5.
6. Strauch B, Zelinka T, Hampf M. et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003; 17 (5): 349–52.
7. Douma S, Petidis K, Doumas M et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational. Lancet 2008; 371 (9628): 1921–6.
8. Käyser SC, Dekkers T, Groenewoud HJ et al. Study Heterogeneity and Estimation of Prevalence of Primary Aldosteronism: A Systematic Review and Meta-Regression Analysis. J Clin Endocrinol Metab 2016; 101 (7): 2826–35.
9. Monticone S, Burrello J, Tizzani D et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol 2017; 69 (14): 1811–20.
10. Funder JW, Carey RM, Mantero F et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101 (5): 1889–916.
11. Samedova Kh.F., Chikhladze N.M., Blinova E.V. et al. Otsenka funktsional'nogo sostoianiia miokarda u bol'nykh arterial'noi gipertoniei na fone giperal'dosteronizma s ispol'zovaniem ortogonal'noi elektrokardiografii. Kardiovaskuliarnaia terapiia i profilaktika. 2006; 5 (2): 15–9 (in Russian).
12. Stowasser M, Bachmann AW, Huggard PR et al. Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance. J Clin Endocrinol Metab 2000; 85 (6): 2160–6.
13. Chikhladze N.M., Favorova O.O., Chazova I.E. Familial type I hyperaldosteronism: clinical observation and literature review. Therapeutic Archive. 2018; 90 (9): 115–22 (in Russian).
14. Schmiemann G, Gebhardt K, Hummers-Pradier E et al. Prevalence of hyperaldosteronism in primary care patients with resistant hypertension. J Am Board Fam Med 2012; 25: 98–103.
15. Sang X, Jiang Y, Wang W et al. Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China. J Hypertens 2013; 31 (7): 1465–72.
16. Catena C, Colussi G, Nadalini E et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 80–5.
17. Milliez P, Girerd X, Plouin PF et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45 (8): 1243–8.
18. Jaffe G, Gray Z, Krishna G et al. Screening Rates for Primary Aldosteronism in Resistant Hypertension. A Cohort Study. Hypertension 2020; 75 (3): 650–9.
Авторы
Н.М. Чихладзе*
Институт клинической кардиологии им. А.Л. Мясникова ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России, Москва, Россия
*novella.cardio@mail.ru
Myasnikov Institute of Clinical Cardiology, National Medical Research Center of Cardiology, Moscow, Russia
*novella.cardio@mail.ru
Институт клинической кардиологии им. А.Л. Мясникова ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России, Москва, Россия
*novella.cardio@mail.ru
________________________________________________
Myasnikov Institute of Clinical Cardiology, National Medical Research Center of Cardiology, Moscow, Russia
*novella.cardio@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.